| Literature DB >> 35215606 |
Zhaowen Liu1,2,3,4, Xiuqiong Chen1,3,4, Zhiqin Huang2, Hongcai Wang1,3,4, Shirui Cao3,4, Chunyang Liu3,4, Huiqiong Yan1,3,4, Qiang Lin1,3,4.
Abstract
In this paper, we developed an organic solvent-free, eco-friendly, simple and efficient one-pot approach for the preparation of amphiphilic conjugates (Ugi-OSAOcT) by grafting octylamine (OCA) to oxidized sodium alginate (OSA). The optimum reaction parameters that were obtained based on the degree of substitution (DS) of Ugi-OSAOcT were a reaction time of 12 h, a reaction temperature of 25 °C and a molar ratio of 1:2.4:3:3.3 (OSA:OCA:HAc:TOSMIC), respectively. The chemical structure and composition were characterized by Fourier transform infrared spectroscopy (FTIR), 1H nuclear magnetic resonance (1H NMR), X-ray diffraction (XRD), thermogravimetry analyser (TGA), gel permeation chromatography (GPC) and elemental analysis (EA). It was found that the Ugi-OSAOcT conjugates with a CMC value in the range of 0.30-0.085 mg/mL could self-assemble into stable and spherical micelles with a particle size of 135.7 ± 2.4-196.5 ± 3.8 nm and negative surface potentials of -32.8 ± 0.4--38.2 ± 0.8 mV. Furthermore, ibuprofen (IBU), which served as a model poorly water-soluble drug, was successfully incorporated into the Ugi-OSAOcT micelles by dialysis method. The drug loading capacity (%DL) and encapsulation efficiency (%EE) of the IBU-loaded Ugi-OSAOcT micelles (IBU/Ugi-OSAOcT = 3:10) reached as much as 10.9 ± 0.4-14.6 ± 0.3% and 40.8 ± 1.6-57.2 ± 1.3%, respectively. The in vitro release study demonstrated that the IBU-loaded micelles had a sustained and pH-responsive drug release behavior. In addition, the DS of the hydrophobic segment on an OSA backbone was demonstrated to have an important effect on IBU loading and drug release behavior. Finally, the in vitro cytotoxicity assay demonstrated that the Ugi-OSAOcT conjugates exhibited no significant cytotoxicity against RAW 264.7 cells up to 1000 µg/mL. Therefore, the amphiphilic Ugi-OSAOcT conjugates synthesized by the green method exhibited great potential to load hydrophobic drugs, acting as a promising nanocarrier capable of responding to pH for sustained release of hydrophobic drugs.Entities:
Keywords: amphiphilic conjugates; nanocarrier; self-assembly; sodium alginate; sustained release
Year: 2022 PMID: 35215606 PMCID: PMC8879484 DOI: 10.3390/polym14040694
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Elemental contents of Ugi-OSAOcT conjugates prepared by the optimum reaction parameters.
| Sample a | b DO (%) | C (% m/m) | H (% m/m) | N (% m/m) | DS (%) |
|---|---|---|---|---|---|
| Ugi-OSA10OcT | 9.51 | 51.5 | 7.45 | 0.89 | 4.8 |
| Ugi-OSA30OcT | 27.76 | 41.69 | 7.17 | 1.96 | 14.8 |
| Ugi-OSA50OcT | 44.25 | 30.36 | 6.77 | 2.1 | 24.3 |
a Subscript refers to the degree of theoretical oxidation of OSA; b the degree of actual oxidation of OSA was determined by the hydroxylamine hydrochloride/sodium hydroxide colorimetric titration method.
Figure 1Schematic illustration of synthesis routes of Ugi-OSAOcT.
Figure 2(A) FTIR spectra of (a) SA, (b) OSA, (c) Ugi-OSA10OcT, (d) Ugi-OSA30OcT, (e) OCA, (f) Ugi-OSA50OcT and (g) OCA+OSA mixture; (B) 1H NMR spectra of (a) OCA (CDCl3), (b)TOSMIC (D2O), (c)SA (D2O), (d)OSA (D2O), (e)Ugi-OSA10OcT (D2O), (f) Ugi-OSA30OcT (D2O) and (g) Ugi-OSA50OcT (D2O).
Optimization of reaction parameters for preparation of OCA-grafted OSA10 (Ugi-OSA10OcT) via Ugi-4CR.
| NOSA10:NOCA:NHAc:NTOSMIC a | t (h) | T (°C) | DS (%) b | Mw c | Mn c | Mw/Mn c | Yield (%) |
|---|---|---|---|---|---|---|---|
| 1:2:2:2.2 | 12 | 25 | 3.3 | 112,671 | 84,132 | 1.34 | 41.3 |
| 1:2.4:2.4:2.6 | 12 | 25 | 4.0 | 121,653 | 92,161 | 1.32 | 52.6 |
| 1:2.8:2.8:3.1 | 12 | 25 | 3.9 | 119,868 | 77,334 | 1.55 | 53.4 |
| 1:2.4:2.4:2.6 | 16 | 25 | 3.8 | 120,848 | 81,654 | 1.48 | 53.3 |
| 1:2.4:2.4:2.6 | 8 | 25 | 2.8 | 111,269 | 73,203 | 1.52 | 46.8 |
| 1:2.4:2.4:2.6 | 12 | 37 | 3.8 | 121,058 | 85,857 | 1.41 | 48.5 |
| 1:2.4:3:3.3 | 12 | 25 | 4.8 | 123,259 | 88,676 | 1.39 | 54.2 |
| 1:2.4:3.5:3.9 | 12 | 25 | 4.8 | 124,512 | 87,685 | 1.42 | 54.7 |
a The molar ratio of reagent corresponding to OSA10:OCA:HAc:TOSMIC; b determined by EA; c determined by GPC (0.05% sodium azide as the mobile phase).
Figure 3(A–C) DS (%), as a function of reaction time after coupling of OCA to OSA10 varying: (A) molar ratio of OCA to OSA at 25 °C; (B) temperature (25 °C and 37 °C) using the molar ratio of 1:2.4:2.4:2.6 (NOSA10:NOCA:NHAc:NTOSMIC); and (C) amount of HAc at constant molar ratio of 1:2.4 (NOSA10:NOCA) and 25 °C. (D) GPC traces of OSA10 and Ugi-OSAOcT conjugates.
Figure 4(A) XRD patterns of SA, OSA and Ugi-OSAOcT conjugates. (B) TGA and DTG curves of SA and Ugi-OSAOcT conjugates.
Figure 5(A) Plots of pyrene fluorescence intensity ratio (I1/I3) vs. the concentration of Ugi-OSAOcT in 0.05 mol/L aqueous NaCl solution at 25 °C; (B) changes in the CMC value of Ugi-OSAOcT micelles in 0.05 mol/L aqueous NaCl solution at 25 °C as a function of DS.
Characteristics of Ugi-OSAOcT micelles (1.0 mg/mL): Data are presented as mean ± SD (n = 3).
| Sample | DS (%) | CMC (mg/mL) | Size (nm) | PDI | Zeta Potential (mV) |
|---|---|---|---|---|---|
| Ugi-OSA10OcT | 4.8 | 0.30 | 196.5 ± 3.8 | 0.43 ± 0.04 | −38.2 ± 0.8 |
| Ugi-OSA30OcT | 14.8 | 0.20 | 178.3 ± 4.5 | 0.45 ± 0.03 | −36.8 ± 0.6 |
| Ugi-OSA50OcT | 24.3 | 0.085 | 135.7 ± 2.4 | 0.37 ± 0.02 | −32.8 ± 0.4 |
Figure 6(A) Size distribution and (B) zeta potential determined with DLS for the blank Ugi-OSAOcT micelles with different DS at 25 °C; (C) TEM; and (D) size distribution for the blank Ugi-OSA50OcT micelles at 25 °C. The mass concentration of Ugi-OSAOcT conjugates was 1.0 mg/mL. Data are presented as mean ± SD (n = 3).
Figure 7Influence of pH on: (A) the size; (B) zeta potential of Ugi-OSAOcT micelles with different DSat 25 °C; (C) the size, PDI and (D) zeta potential of Ugi-OSAOcT micelles over time at 25 °C in PBS (pH 7.4). The mass concentration of Ugi-OSAOcT conjugates was 1.0 mg/mL. Data are presented as mean ± SD (n = 3).
Characteristics of IBU loaded Ugi-OSAOcT micelles. Data are presented as mean ± SD (n = 3).
| Sample | Drug/Polymer ( | DL (%) | EE (%) | Size (nm) | PDI | Zeta Potential |
|---|---|---|---|---|---|---|
| Ugi-OSA50OcT | 1:10 | 3.9 ± 0.4 | 40.8 ± 1.6 | 142.5 ± 3.5 | 0.37 ± 0.06 | −34.8 ± 1.4 |
| Ugi-OSA50OcT | 2:10 | 8.2 ± 0.5 | 44.6 ± 1.8 | 150.7 ± 2.3 | 0.41 ± 0.03 | −35.2 ± 1.8 |
| Ugi-OSA50OcT | 3:10 | 14.6 ± 0.3 | 57.2 ± 1.3 | 160.3 ± 5.7 | 0.35 ± 0.02 | −38.8 ± 0.6 |
| Ugi-OSA50OcT | 5:10 | 19.3 ± 1.2 | 52.4 ± 1.5 | 154.6 ± 4.8 | 0.36 ± 0.05 | −36.7 ± 1.5 |
| Ugi-OSA10OcT | 3:10 | 10.9 ± 0.4 | 40.8 ± 1.6 | 210.8 ± 5.2 | 0.45 ± 0.03 | −42.5 ± 0.3 |
| Ugi-OSA30OcT | 3:10 | 13.2 ± 0.5 | 50.6 ± 1.8 | 198.6 ± 4.8 | 0.43 ± 0.03 | −42.3 ± 0.5 |
Figure 8(A) Size distribution determined with DLS and (B) TEM for IBU-loaded Ugi-OSA50OcT micelles at 25 °C. The feeding mass ratio of IBU to Ugi-OSA50OcT was 3:10.
Figure 9In vitro release profile of: (A) free IBU and loaded IBU from Ugi-OSAOcT micelles with different DS at 37 °C in PBS (pH 7.4) containing Tween 80 (0.5% w/v) and (B) loaded IBU from Ugi-OSA50OcT micelles at 37 °C in PBS containing Tween 80 (0.5% w/v) at different pH values. Data are expressed as mean ± SD (n = 3).
Figure 10In vitro cytotoxicity of Ugi-OSAOcT conjugates, OSA and SA at various concentrations against RAW 264.7 cells after incubation for 48 h: * represents p < 0.05, indicating significant difference.